AbCellera discovers and develops therapeutic antibodies using a proprietary platform that combines microfluidics, high-throughput screening and machine learning. The company partners with pharmaceutical and biotech firms to identify antibody candidates against disease targets, often from natural immune responses. Its technology aims to accelerate early discovery and expand the pool of viable drug candidates. Revenue comes mainly from research partnerships, milestones and potential royalties rather than marketed drugs of its own.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 17.1 | — | -34.7 | — |
| Q3 2025 | 9 | — | -57.1 | — |
| Q4 2025 | 44.9 | — | -8.9 | — |
| Q1 2026 | 8.3 | — | -43.2 | — |
| Q2 2026 | 4 | -76.3% | -55.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Iovance Biotherapeutics, Inc. (IOVA), Wix.com Ltd. (WIX), Cal-Maine Foods, Inc. (CALM), Sportradar Group AG (SRAD), SkyWest, Inc. (SKYW), BancFirst Corporation (BANF)